Who Paid My Doc
Terlivaz
Drug Critical Care
NDC 43825-200-01
General payments
$5,249,230
Research payments
$3,564,322
Through program year 2025, $5,249,230 in general payments and $3,564,322 in research payments were reported against Terlivaz (Critical Care).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
7 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $1,919,910 | 6,361 |
| 2025 | Research | $952,009 | 4 |
| 2024 | General | $1,671,967 | 5,145 |
| 2024 | Research | $1,312,630 | 6 |
| 2023 | General | $1,285,482 | 3,443 |
| 2023 | Research | $1,299,683 | 10 |
| 2022 | General | $371,871 | 769 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.
The top 5 of 76 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
The top 5 of 50 states; each share is of general payments naming this product in 2025 where a state was reported.
Records
15,718 general · 20 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.